eISSN 2329-0358


Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor

Krzysztof Gawroński, Piotr Rzepecki, Waldemar Sawicki, Jarosław Wajs

(Department of Hematology and Bone Marrow Transplantation Unit, Military Medical Institute, Warsaw, Poland)

Ann Transplant 2017; 22:296-302

DOI: 10.12659/AOT.901875

Published: 2017-05-12

BACKGROUND: To increase the number of circulating hematopoietic stem cells (HSC) in the blood, mobilization treatments are currently being used. G-CSF and G-CSF plus chemotherapy are the most common methods of hematopoietic stem cells separation used in Poland.
MATERIAL AND METHODS: We observed patients who failed an effective hematopoietic stem cell mobilization with G-CSF or with G-CSF plus chemotherapy. The separation was considered unsuccessful if within a period of 4 consecutive days of separation, the number of obtained CD 34+ cells was lower than 2.0×10^6/kg of bodyweight. The study involved 32 patients whose CD34+ cells were collected and the collection for autologous transplantation failed. The study included 20 men and 12 women. Among all 32 patients, 28 had multiple myeloma, 3 had DLBCL lymphoma, and 1 had Hodgkin’s disease.
RESULTS: Separation was unsuccessful in only 3 patients; the remaining 29 achieved an average of 4.83×10^6 CD34+ cells per kg of bodyweight. We conclude that plerixafor is an important tool in obtaining sufficient quantities of cells for hematopoietic stem cells separation.
CONCLUSIONS: The use of plerixafor is a sufficient and safe option for stem cells mobilization in autologous transplantations.

Keywords: Hematopoietic Cell Growth Factors, Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation